Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.280
-0.070 (-5.19%)
At close: Aug 24, 2026, 4:00 PM EDT
1.310
+0.030 (2.34%)
Pre-market: Aug 25, 2026, 5:27 AM EDT
PACB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 159.27 | 160.01 | 154.01 | 200.52 | 128.3 | 130.51 | |
Revenue Growth | 2.02% | 3.89% | -23.19% | 56.29% | -1.69% | 65.43% |
Cost of Revenue | 112.41 | 105.15 | 106.34 | 142.32 | 74.83 | 71.35 |
Gross Profit | 46.86 | 54.85 | 47.67 | 58.2 | 53.47 | 59.17 |
Selling, General & Admin | 131.3 | 137.69 | 175.02 | 169.82 | 160.85 | 124.12 |
Research & Development | 88.96 | 95.21 | 134.92 | 187.17 | 193 | 112.9 |
Amortization of Goodwill & Intangibles | 4.06 | 369.44 | 27.4 | 8.14 | 0.73 | 0.31 |
Other Operating Expenses | 0.09 | 4.18 | 1 | 3.44 | 3.71 | - |
Operating Expenses | 224.4 | 606.51 | 338.34 | 368.56 | 358.29 | 237.33 |
Operating Income | -177.54 | -551.66 | -290.66 | -310.37 | -304.82 | -178.16 |
Interest Expense | -7.33 | -6.95 | -13.41 | -14.34 | -14.69 | -12.53 |
Other Non Operating Income (Expenses) | 7.91 | 10.39 | 10.74 | 19.84 | 7.39 | 4.1 |
EBT Excluding Unusual Items | -176.95 | -548.22 | -293.34 | -304.86 | -312.12 | -186.59 |
Merger & Restructuring Charges | 14.6 | -5.9 | - | -9.04 | - | -83.13 |
Impairment of Goodwill | - | - | -144.5 | - | - | - |
Gain (Loss) on Sale of Investments | 1.9 | 4.37 | 13.04 | 12.84 | 0.24 | -4.01 |
Asset Writedown | - | -15 | -40 | - | - | - |
Other Unusual Items | - | 18.7 | 155.26 | -17.09 | -2.38 | -1.14 |
Pretax Income | -130.56 | -546.06 | -309.54 | -318.16 | -314.25 | -274.87 |
Income Tax Expense | 0.83 | 0.32 | 0.32 | -11.42 | - | -93.65 |
Net Income | -131.39 | -546.38 | -309.85 | -306.74 | -314.25 | -181.22 |
Net Income to Common | -131.39 | -546.38 | -309.85 | -306.74 | -314.25 | -181.22 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 305 | 300 | 274 | 254 | 225 | 204 |
Shares Outstanding (Diluted) | 305 | 300 | 274 | 254 | 225 | 204 |
Shares Change | 5.75% | 9.28% | 8.22% | 12.95% | 10.00% | 16.67% |
EPS (Basic) | -0.43 | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 |
EPS (Diluted) | -0.43 | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -123.42 | -113.92 | -212.25 | -268.02 | -279.96 | -117.11 |
Free Cash Flow Per Share | -0.41 | -0.38 | -0.77 | -1.06 | -1.25 | -0.57 |
Gross Margin | 29.42% | 34.28% | 30.95% | 29.02% | 41.68% | 45.33% |
Operating Margin | -111.47% | -344.78% | -188.73% | -154.78% | -237.58% | -136.51% |
Profit Margin | -82.49% | -341.47% | -201.18% | -152.97% | -244.93% | -138.85% |
Free Cash Flow Margin | -77.49% | -71.20% | -137.81% | -133.66% | -218.20% | -89.73% |
EBITDA | 199.18 | -169.23 | -249.48 | -290.64 | -294.43 | -170.58 |
EBITDA Margin | 125.06% | -105.76% | -161.98% | -144.94% | -229.47% | -130.70% |
D&A For EBITDA | 376.71 | 382.44 | 41.19 | 19.72 | 10.39 | 7.58 |
EBIT | -177.54 | -551.66 | -290.66 | -310.37 | -304.82 | -178.16 |
EBIT Margin | -111.47% | - | -188.73% | -154.78% | -237.58% | -136.51% |
Revenue as Reported | 159.27 | 160.01 | 154.01 | 200.52 | 128.3 | 130.51 |